VIVUS News

VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has entered into definitive agreements dated August 5, 2008 with ...

Successful investing requires you to think independently and stick to your convictions.

Vivus Inc. 's diabetes drug Qnexa did well in a mid-stage clinical trial in obese patients.

Stocks continued to move lower in the first few hours of trading on Thursday as lower initial jobless claims and declining oil prices failed to inspire buyers.

Commonwealth Bank of Australia Issue of EUR 5,000,000 Floating Rate Notes due May 2009 Series 3422 Tranche 1 MTN ISSUE NAME.

Jun 13, 2008 - VIVUS, Inc a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that, Peter Tam, senior vice president of Product and ...

Main Category: Diabetes Also Included In: Conferences Article Date: 06 Jun 2008 - 4:00 PDT VIVUS, Inc a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, ...

Tim Morris - VP Finance and CFO Leland Wilson - President and CEO Peter Tam - SVP Product & Corporate Development Analysts Corey Kasimov - JPMorgan Ian Sanderson - Cowen and Company Ruthanne Roussel - Robins ...

Vivus was down 79 cents, or 10.7 percent, to $6.57. The Mountain View developer of drugs for sexual dysfunction and obesity was cut to "market perform" from "outperform" by Wachovia analysts, who said investors ...

“Obesity is a major epidemic that significantly contributes to early death due to cardiovascular disease, diabetes, and cancer. Our phase 3 program is designed to evaluate weight loss in these patients and potential benefit on their co-morbidities”

VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed enrollment in the final of three phase 3 studies of ... via BioSpace

“This experience will be helpful as we look to the future”

San Francisco Business Times - by Steven E.F. Brown Drug company Vivus Inc. , which focuses on treatments for obesity and sexual problems, added Charles Casamento, the former CEO of Osteologix Inc. via Bizjournals

“We are pleased to have entered into this collaboration with Vivus that provides full funding for phase 3 while avoiding significant shareholder dilution.”

VIVUS, Inc. announced today that it has entered into a $30 million funding collaboration with Deerfield Management . via BioSpace

Last week, tiny drugmaker VIVUS said it had completed enrollment for a phase 3 study of its anti-obesity drug Qnexa. via Fool.com

VIVUS, Inc. announced today that it has successfully completed and reached agreement with the U.S. Food and Drug Administration regarding the Special Protocol Assessment for the phase 3 efficacy trials for ... via BioSpace

“We anticipate that the results of the study will be available in the second half of 2009.”

March 27, 2008 - VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed enrollment in the first of two ... via Med Ad News

Author: 123jump.com Staff 123jump.com Last Update: 4:01 PM EST March 07 2008 Ciena surged 11% after it reported first quarter revenue increase of 38% to $227.4 million and net income increase of 160%. Ciena ... via Ticker

MOUNTAIN VIEW, Calif.-- --VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced - BOSTON-- --Exclusive new research from ... via Business Wire

Timothy E. Morris, 650-934-5200 Chief Financial Officer or Trout Group Ian Clements , 415-392-3385 or Brian Korb , 646-378-2923 VIVUS, Inc a pharmaceutical company dedicated to the development and ... via PR-inside.com

BioTime, Inc. announced it has signed a licensing agreement with the Wisconsin Alumni Research Foundation to 173 patents and patent - VIVUS Initiates Extension Study with Qnexa for Diabetes MOUNTAIN VIEW, ... via Business Wire

“The initiation of the EQUATE study completes our plans for phase 3 studies of Qnexa. The EQUATE study will evaluate two doses of Qnexa over 6 months and should give us an early look at the outcomes of the larger pivotal phase 3 studies”

Timothy E. Morris, 650-934-5200 Chief Financial Officer or Trout Group Ian Clements , 415-392-3385 Brian Korb , 646-378-2923 VIVUS, Inc. via PR-inside.com